- General information enquiries
- Call 00 800 6 7 8 9 10 11
- E-mail your questions
European Commission
Public Health
Accessibility tools
Service tools
Language selector
- Current languageen
Navigation path
- European Commission
- Public health
- Reference documents
- Register
- Orphan products
- N-[(1R)-1-phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}q
Pharmaceuticals - Community Register
Community register of orphan medicinal products | GRANTED |
Product information |
N-[(1R)-1-phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}quinazolin-2-amine
| EU orphan designation number: | EU/3/17/1868
|
| Active ingredient: | N-[(1R)-1-phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}quinazolin-2-amine |
| Indication: | Treatment of fragile X syndrome |
| Sponsor: | Sentinel Oncology Limited
23 Science Park, Suite 52, Milton Road, Cambridge CB4 0EY, United Kingdom |
Public summary of scientific opinion
European Commission procedures |
| Close date procedure | Procedure type | EMEA number | Decision | summary publ | decision docs | annex |
| 24/04/2017 | Orphan designation | EMA/OD/293/16 | (2017)2787 of 20/04/2017 |
CONTACT
EU links
Directorate General Health & Consumers